Small Molecules, Big Impact: The Power of Tyrosine Kinase Inhibitors to Inhibit HER2 Signaling and Cross the Blood-Brain Barrier
In addition to large protein-based antibodies, small molecule drugs known as Tyrosine Kinase Inhibitors (TKIs) play a vital role in treating HER2-positive breast malignancy. Unlike monoclonal antibodies that bind to the exterior of the cell, TKIs are oral medications that can penetrate the cell membrane and directly block the enzyme (tyrosine kinase) inside the cell that is responsible for...
0 Комментарии 0 Поделились 513 Просмотры 0 предпросмотр